U.S. Markets open in 2 hrs 53 mins

Pluristem Therapeutics Inc. (PSTI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.563+0.003 (+0.192%)
At close: 3:59PM EDT
People also watch
CUROPXAOSIRATHXPLX

Pluristem Therapeutics Inc.

Building No. 5
MATAM Advanced Technology Park
Haifa 31905
Israel
972 7 4710 8607
http://www.pluristem.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees175

Key Executives

NameTitlePayExercisedAge
Mr. Zami AbermanChairman & Co-Chief Exec. OfficerN/AN/A63
Mr. Yaky YanayCo-Chief Exec. Officer, Pres & DirectorN/AN/A46
Mr. Erez EgoziCFO, Treasurer & Sec.N/AN/A43
Efrat KaduriHead of Investor & PRN/AN/AN/A
Dr. Hillit Mannor Shachar M.D., M.B.A.VP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Corporate Governance

Pluristem Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.